Title : Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.

Pub. Date : 2016 Jan 10

PMID : 26551344






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The systemic administration of PEG-PLGA or PEG-PLGA/PLGA NPs containing sorafenib twice per week for a period of 4 weeks efficiently ameliorated liver fibrosis, as indicated by decreased alpha-smooth muscle actin (alpha-SMA) content and collagen production in the livers of CCl4-treated mice. Sorafenib actin alpha 2, smooth muscle, aorta Mus musculus
2 The systemic administration of PEG-PLGA or PEG-PLGA/PLGA NPs containing sorafenib twice per week for a period of 4 weeks efficiently ameliorated liver fibrosis, as indicated by decreased alpha-smooth muscle actin (alpha-SMA) content and collagen production in the livers of CCl4-treated mice. Sorafenib actin alpha 2, smooth muscle, aorta Mus musculus